Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT: Intensive vs Standard Therapy in High-Risk T2DM
NCT04286399Phase 4Recruiting
- Sponsor
- National Heart Centre Singapore
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of RAASi + beta-blocker + SGLT2i (ADOPT regimen), carvedilol in type 2 diabetes mellitus (T2DM), sponsored by National Heart Centre Singapore. Started Jul 2019; status: recruiting.
02
Drugs
RAASi + beta-blocker + SGLT2i (ADOPT regimen)carvedilol
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04286399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286399.